These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35696783)

  • 41. Natural Products Lysobactin and Sorangicin A Show
    Sullivan JR; Yao J; Courtine C; Lupien A; Herrmann J; Müller R; Behr MA
    Microbiol Spectr; 2022 Dec; 10(6):e0267222. PubMed ID: 36342177
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antimicrobial properties of basidiomycota macrofungi to
    Millar BC; Nelson D; Moore RE; Rao JR; Moore JE
    Int J Mycobacteriol; 2019; 8(1):93-97. PubMed ID: 30860186
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improved Clinical Outcome After Treatment of Mycobacterium abscessus Complex Pulmonary Disease in Children With Cystic Fibrosis.
    Chacko A; Wen SCH; Hartel G; Kapur N; Wainwright CE; Clark JE
    Pediatr Infect Dis J; 2019 Jul; 38(7):660-666. PubMed ID: 30724835
    [TBL] [Abstract][Full Text] [Related]  

  • 44.
    Degiacomi G; Sammartino JC; Chiarelli LR; Riabova O; Makarov V; Pasca MR
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31766758
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interaction of South Asian spices with conventional antibiotics: Implications for antimicrobial resistance for
    Moore RE; Millar BC; Panickar JR; Moore JE
    Int J Mycobacteriol; 2018; 7(3):257-260. PubMed ID: 30198506
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intrapulmonary Treatment with Mycobacteriophage LysB Rapidly Reduces Mycobacterium abscessus Burden.
    Hurst-Hess K; Walz A; Yang Y; McGuirk H; Gonzalez-Juarrero M; Hatfull GF; Ghosh P; Ojha AK
    Antimicrob Agents Chemother; 2023 Jun; 67(6):e0016223. PubMed ID: 37154689
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mycobacterium abscessus Displays Fitness for Fomite Transmission.
    Malcolm KC; Caceres SM; Honda JR; Davidson RM; Epperson LE; Strong M; Chan ED; Nick JA
    Appl Environ Microbiol; 2017 Oct; 83(19):. PubMed ID: 28754702
    [No Abstract]   [Full Text] [Related]  

  • 48. Clinical significance of respiratory isolates for Mycobacterium abscessus complex from pediatric patients.
    Do PC; Nussbaum E; Moua J; Chin T; Randhawa I
    Pediatr Pulmonol; 2013 May; 48(5):470-80. PubMed ID: 22833551
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis.
    Leung JM; Olivier KN
    Curr Opin Pulm Med; 2013 Nov; 19(6):662-9. PubMed ID: 24048085
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advances in the management of pulmonary disease due to Mycobacterium abscessus complex.
    Koh WJ; Stout JE; Yew WW
    Int J Tuberc Lung Dis; 2014 Oct; 18(10):1141-8. PubMed ID: 25216826
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Microscopic polyangiitis secondary to Mycobacterium abscessus in a patient with bronchiectasis: a case report.
    Addy C; Doran G; Jones AL; Wright G; Caskey S; Downey DG
    BMC Pulm Med; 2018 Nov; 18(1):170. PubMed ID: 30453935
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Children With Cystic Fibrosis Are Infected With Multiple Subpopulations of Mycobacterium abscessus With Different Antimicrobial Resistance Profiles.
    Shaw LP; Doyle RM; Kavaliunaite E; Spencer H; Balloux F; Dixon G; Harris KA
    Clin Infect Dis; 2019 Oct; 69(10):1678-1686. PubMed ID: 30689761
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Recchia D; Stelitano G; Stamilla A; Gutierrez DL; Degiacomi G; Chiarelli LR; Pasca MR
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902066
    [No Abstract]   [Full Text] [Related]  

  • 54. Prevention of transmission of Mycobacterium abscessus among patients with cystic fibrosis.
    Gross JE; Martiniano SL; Nick JA
    Curr Opin Pulm Med; 2019 Nov; 25(6):646-653. PubMed ID: 31436542
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human infections due to nontuberculous mycobacteria: the infectious diseases and clinical microbiology specialists' point of view.
    Guglielmetti L; Mougari F; Lopes A; Raskine L; Cambau E
    Future Microbiol; 2015; 10(9):1467-83. PubMed ID: 26344005
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment outcomes of macrolide-susceptible Mycobacterium abscessus lung disease.
    Choi H; Jhun BW; Kim SY; Kim DH; Lee H; Jeon K; Kwon OJ; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
    Diagn Microbiol Infect Dis; 2018 Apr; 90(4):293-295. PubMed ID: 29329759
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug susceptibility patterns of rapidly growing mycobacteria isolated from skin and soft tissue infections in Venezuela.
    Da Mata-Jardín O; Angulo A; Rodríguez M; Fernández-Figueiras S; de Waard JH
    Eur J Clin Microbiol Infect Dis; 2020 Mar; 39(3):433-441. PubMed ID: 31741101
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of
    Aguilera-Correa JJ; Boudehen YM; Kremer L
    Antimicrob Agents Chemother; 2023 Sep; 67(9):e0040223. PubMed ID: 37565746
    [No Abstract]   [Full Text] [Related]  

  • 59. Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessus.
    Negatu DA; Beuchel A; Madani A; Alvarez N; Chen C; Aragaw WW; Zimmerman MD; Laleu B; Gengenbacher M; Dartois V; Imming P; Dick T
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0067621. PubMed ID: 34001512
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease.
    Lyu J; Kim BJ; Kim BJ; Song JW; Choi CM; Oh YM; Lee SD; Kim WS; Kim DS; Shim TS
    Respir Med; 2014 Nov; 108(11):1706-12. PubMed ID: 25245792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.